Sequential Expansion of Comparative Effectiveness of Anticoagulants
Completed
Conditions studied: Atrial Fibrillation
In brief
This cohort study is the sequential expansion of the comparative effectiveness study of oral anticoagulants and plans to identify initiators of oral anticoagulants using electronic claims data from a commercial insurance database to quantify associations between anticoagulant choice (warfarin and dabigatran) and the occurrence of selected outcomes in patients with non-valvular atrial fibrillation at risk for stroke.
Key facts
- Study ID
- NCT02081807
- Run by
- Boehringer Ingelheim
- People needed
- 221228
- Starts
- 2014-03-07
- Expected to finish
- 2017-11-01
- Last updated by the study team
- 2019-10-02
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- A recorded diagnosis of atrial fibrillation.
- Initiation of anticoagulant medication (dabigatran (or other new oral anticoagulants as they become available) or warfarin).
- At least 18 years of age on the date of anticoagulant initiation.
- Congestive Heart Failure, Hypertension, Age > 75, Diabetes Mellitus, Prior Stroke or Transient Ischemic Attack, Vascular Disease, Age 65-74, Sex Category (CHA2DS2-VASc) score at least 1
You may not qualify if…
- Patients with missing or ambiguous age or sex information.
- Patients with evidence of valvular disease.
- Patients with less than 12 months enrolment preceding the date of anticoagulant initiation
- Patients with a dispensing of any oral anticoagulant during the 12 months preceding the date of anticoagulant initiation
- Patients with a nursing home stay during the 12 months preceding the date of anticoagulant initiation
Where it is running
- Brigham and Women's Hospital — Boston, Massachusetts, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.